Transcriptome analysis reveals the differential inflammatory effects between propofol and sevoflurane during lung cancer resection: a randomized pilot study

• Published in: World journal of surgical oncology 2023-01, Vol.21 (1), p.8-8, Article 8
• Main Authors: Wang, Sufang, Li, Mengjiao, Cai, Suna, Zhang, Wei
• Format: Article
• Language: English
• Subjects: Anesthetics; Carcinogenesis; Care and treatment; Chemokines; Diagnosis; Dosage and administration; Gene Expression Profiling; Health aspects; Humans; Inflammatory effects; Lung cancer; Lung Neoplasms - genetics; Lung Neoplasms - surgery; Methyl Ethers - adverse effects; Patient outcomes; Pilot Projects; Pneumonectomy; Propofol; Propofol - adverse effects; RNA-seq; Sevoflurane; Sevoflurane - adverse effects
• ISSN: 1477-7819; 1477-7819
• DOI: 10.1186/s12957-023-02891-4

Propofol and sevoflurane are two commonly used perioperative anesthetics. Some studies have found that these anesthetic drugs affect tumorigenesis. Previous studies have mostly focused on in vitro experiments, and the specimens collected were mainly peripheral body fluids, lacking direct evidence of the impact of anesthetic drugs on human tissues. This study aimed to elucidate the effects of propofol and sevoflurane on lung cancer using next-generation sequencing through an in vivo experiment. Patients were randomly assigned to a group receiving either propofol or sevoflurane during surgery. Then, the patients' tumor and paired normal samples were collected and sequenced by next-generation sequencing. Differentially expressed genes (DEG) were analyzed by two statistical models, followed by cluster analysis, PCA, Gene Ontology, and KEGG pathway analysis. Candidate genes were confirmed by qRT-PCR. The demographic data of the two study groups were not statistically significant. Through single-factor model analysis, 810 DEG in the propofol group and 508 DEG in the sevoflurane group were obtained. To better reflect the differential effects between propofol and sevoflurane while reducing the false-positive DEG, we used multifactor model analysis, which resulted in 124 DEG. In PCA and cluster analysis, four groups (propofol cancer group, propofol normal group, sevoflurane cancer group, sevoflurane normal group) were separated adequately, indicating the accuracy of the analysis. We chose seven significant pathways (cellular response to interleukin-1, chemokine-mediated signaling pathway, chemokine signaling pathway, cytokine-cytokine receptor interaction, inflammatory response, immune response, and TNF signaling pathway) for downstream analysis. Based on the pathway analysis, three candidate genes (CXCR1, CXCL8, and TNFAIP3) were chosen, and their qRT-PCR results were consistent with the sequencing results. Through RNA-seq analysis, the effects of propofol and sevoflurane during lung cancer resection were different, mainly in inflammatory-related pathways, which might be possibly by targeting CXCL8. Trial registry number was ChiCTR1900026213 .